Richard A. Heyman, a director at Oric Pharmaceuticals, Inc. (NASDAQ:ORIC), executed a sale of 300 shares of the company’s common stock on July 6, 2026, resulting in a total transaction value of $3,600. The shares were sold at a per-share price of $12.00. This transaction was facilitated under a Rule 10b5-1 trading plan, a mechanism adopted jointly by Mr. Heyman and RAHD Capital, LLC. The stock involved in this sale is held of record by RAHD Capital, LLC, an entity where Mr. Heyman retains both voting and investment authority. Post-transaction, Mr. Heyman’s holdings include an indirect stake of 212,772 shares through RAHD Capital, LLC, alongside a direct holding of 41,800 shares. This divestment occurs against a backdrop of heightened institutional interest, with multiple analyst firms recently upgrading or initiating coverage on ORIC, citing promising clinical data for rinzimetostat, a drug in development for prostate cancer. Goldman Sachs upgraded the stock to a Buy rating with a $15.00 price target, while Stifel initiated coverage with a Buy rating and a $14.00 target, emphasizing rinzimetostat’s potential in combination with darolutamide for metastatic castration-resistant prostate cancer. H.C. Wainwright reiterated its Buy rating with a $25 price target, noting that Fulcrum Therapeutics’ discontinuation of its PRC2 inhibitor program may alter ORIC’s competitive landscape. Cantor Fitzgerald maintained an Overweight rating, highlighting the significance of Pfizer’s mevrometostat trial results for ORIC’s prospects. Additionally, ORIC presented preclinical data at the American Association for Cancer Research Annual Meeting, demonstrating rinzimetostat’s activity in prostate cancer and noting that PRC2 activity is prevalent early in disease development and persists during progression. These developments underscore growing interest in ORIC’s research and its potential impact in the oncology sector. The stock closed at $10.90, reflecting a +0.02 (+0.18%) change, with after-hours trading showing no movement.
Key Points
- Richard Heyman sold 300 shares at $12.00 per share, totaling $3,600, under a Rule 10b5-1 plan adopted with RAHD Capital, LLC.
- Multiple analyst firms upgraded or initiated coverage on ORIC, citing clinical data for rinzimetostat in prostate cancer and competitive landscape shifts.
- ORIC presented preclinical data at the American Association for Cancer Research Annual Meeting, highlighting PRC2 activity in prostate cancer development.
Risks
- Clinical trial outcomes for rinzimetostat and mevrometostat remain critical, with Pfizer’s results directly impacting ORIC’s prospects.
- Competitive dynamics may shift due to other firms’ program discontinuations, affecting ORIC’s market position.
- Insider sales, while pre-arranged, may signal caution among directors regarding near-term valuation or market conditions.